Healthcare Services

Global Cancer Profiling Market Expected to Reach $25.62 Billion by 2030 with 11.3% CAGR

March 30, 2026 by Marketing Posting

The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.

How Large Is The Cancer Profiling Market Projected To Become By 2030 Based On Its 2026 Valuation?

The cancer profiling market size has experienced rapid growth in recent years. It is anticipated to expand from $15 billion in 2025 to $16.67 billion in 2026, demonstrating a compound annual growth rate (CAGR) of 11.1%. The increase observed in the historic period stems from escalating cancer incidence rates, the proliferation of molecular diagnostics laboratories, the early embrace of genomic testing in oncology, an uptick in research-based cancer profiling, and the growing accessibility of diagnostic platforms.

The cancer profiling market size is anticipated to undergo swift expansion in the next few years. This market is projected to reach $25.62 billion by 2030, expanding at a compound annual growth rate (CAGR) of 11.3%. The expansion during the forecast period is primarily driven by several factors, including the escalating demand for precision medicine approaches, the broader application of companion diagnostics, the rising utilization of liquid biopsy technologies, increasing investments in oncology diagnostics, and the growing incorporation of profiling into routine clinical workflows. Key trends anticipated in the forecast period involve the increasing adoption of NGS-based cancer profiling, the expanding use of comprehensive genomic panels, the growing integration of AI in data interpretation, the wider availability of personalized oncology diagnostics, and a heightened emphasis on early molecular detection.

Download the Free Sample Report to Explore Key Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=9912&type=smp

Which Market Drivers Are Supporting The Expansion Of The Cancer Profiling Market?

The expanding occurrence of cancer is projected to boost the growth of the cancer profiling market in the foreseeable future. Cancer incidence refers to the count of new cancer cases identified within a particular population over a specified duration. The heightened incidence of cancer is attributable to factors such as urbanization, an expanding elderly demographic, evolving lifestyle choices, alongside environmental and genetic influences. Cancer profiling serves to identify specific molecular or genetic alterations in a tumor, such as gene mutations or other changes in tumor DNA, which is advantageous throughout the cancer treatment cycle. For example, in July 2024, the Australian Institute of Health and Welfare, an Australia-based government agency, stated that an estimated 165,000 Australians received a new cancer diagnosis in 2023, equating to over 450 cases daily, with males making up approximately 55% of these diagnoses. Hence, the rising incidence of cancer is propelling the growth of the cancer profiling market.

What Segment Groups Are Identified Within The Cancer Profiling Market?

The cancer profiling market covered in this report is segmented –

1) By Technology: Immunoassays, PCR (Polymerized Chain Reaction), NGS (Next-Generation Sequencing), Microarrays, In-Situ Hybridization

2) By Biomarker Type: Genomic Biomarkers, Protein Biomarkers

3) By Cancer Type: Breast Cancer, Lung Cancer, Colorectal Cancer, Prostate Cancer, Melanoma Cancer, Other Cancers

4) By Application: Research Applications, Clinical Applications, Diagnostics, Prognostics, Other Applications

Subsegments:

1) By Immunoassays: Enzyme-Linked Immunosorbent Assay (ELISA), Western Blotting, Luminex xMAP Technology

2) By PCR (Polymerase Chain Reaction): Quantitative PCR (qPCR), Digital PCR (dPCR), Reverse Transcription PCR (RT-PCR)

3) By NGS (Next-Generation Sequencing): Whole Genome Sequencing (WGS), Whole Exome Sequencing (WES), Targeted Sequencing, RNA Sequencing (RNA-Seq)

4) By Microarrays: DNA Microarrays, RNA Microarrays, SNP Arrays

5) By In-Situ Hybridization: Fluorescence In-Situ Hybridization (FISH), Chromogenic In-Situ Hybridization (CISH)

What Trends Are Advancing Progress In The Cancer Profiling Market?

Leading companies within the cancer profiling market are increasingly concentrating on technological advancements, such as simultaneous whole-exome sequencing (WES) and whole-transcriptome sequencing (WTS) assays. These innovations aim to deliver more exhaustive, tissue-conservative, and clinically relevant molecular diagnostics essential for precision oncology. These assays integrate DNA (exome) and RNA (transcriptome) analysis into a single workflow, allowing for the detection of genomic variants including SNVs, indels, and copy-number alterations, alongside gene expression or fusion events, distinguishing them from traditional NGS tests that typically require separate assays or limited gene panels. For example, in November 2024, Caris Life Sciences, a US-based precision medicine company, received FDA approval for MI Cancer Seek. This NGS in vitro diagnostic performs WES and WTS concurrently. The assay uses total nucleic acid (TNA) from FFPE tumor tissue to detect single-nucleotide variants, insertions or deletions across 228 genes, microsatellite instability (MSI), tumor mutational burden (TMB), and copy-number amplifications in breast cancer. Through the integration of DNA and RNA profiling into one test, it preserves tissue, offers clinically actionable companion diagnostic (CDx) indications across multiple tumor types, and speeds up therapy selection by providing a unified genomic blueprint.

Which Companies Hold Significant Positions In The Cancer Profiling Market?

Major companies operating in the cancer profiling market are Illumina Inc., Qiagen NV, NeoGenomics Inc., Sysmex Corporation, HTG Molecular Diagnostics Inc., Caris Life Sciences, NanoString Technologies Inc., Guardant Health Inc., Foundation Medicine Inc., Roche Diagnostics Corporation, F. Hoffmann-La Roche Ltd., Thermo Fisher Scientific Inc., Genscript Biotech Corporation, Tempus Labs Inc., Hologic Inc., Predictive Oncology Inc., Abbott Laboratories, Agilent Technologies Inc., PerkinElmer Inc., Siemens Healthineers, Genomic Health Inc., Natera Inc., ArcherDX Inc., Personal Genome Diagnostics Inc., Enzo Biochem Inc., Cancer Genetics Inc., OncoDNA SA, Ribomed Biotechnologies Inc., Biocartis Group NV, N-of-One Inc., Cynvenio Biosystems Inc., Inivata Ltd., Burning Rock Biotech Limited, PathAI Inc., GENEWIZ Inc., Genoptix Inc., OmniSeq Comprehensive, Resolution Bioscience, OncoCyte Corporation

Read the full cancer profiling market report here:

https://www.thebusinessresearchcompany.com/report/cancer-profiling-global-market-report

How Is The Cancer Profiling Market Distributed Across Key Geographic Regions?

North America was the largest region in the cancer profiling market in 2025. The regions covered in the cancer profiling market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Tailored Cancer Profiling Market Research Report For Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=9912&type=smp

Browse Through More Reports Similar to the Global Cancer Profiling Market 2026, By The Business Research Company

Hydraulics Global Market Report

https://www.thebusinessresearchcompany.com/report/hydraulics-global-market-report

Smart Elevators Global Market Report

https://www.thebusinessresearchcompany.com/report/smart-elevators-global-market-report

Hydraulic Pumps Global Market Report

https://www.thebusinessresearchcompany.com/report/hydraulic-pumps-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795